OVID News and Press, Ovid Therapeutics Inc. From 11/08/19

Ovid Therapeutics (NASDAQ: OVID ): Q3 GAAP EPS of -$0.43 misses by $0.06 . More news on: Ovid Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Announced Positive Initial Results from the Ongoing ENDYMION trial with OV935 (Soticlestat) in Rare Epilepsies; Sustained and Progressively-Improving Median Seizure Frequency Reduction with Prolonged Treatment in Difficult-to-Treat Patient Population Strengthened Financial Position with ...

Amit Rakhit, M.D., MBA, Promoted to President Timothy Daly Promoted to Executive Vice President, Finance NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of peop...

According to industry and sector data analysed by GlobalData, Merck's ( MRK ) Keytruda will reportedly become the world's top-selling drug by 2025, with estimated sales of over $22 billion. Wall Street consensus estimate pegs nearly $20 billion annual sales for Keytruda by 2023. Bristol-Myer...

Gainers:  electroCore (NASDAQ: ECOR ) +43% . Avaya Holdings (NYSE: AVYA ) +26% . RingCentral (NYSE: RNG ) +26% . Exela Technologies (NASDAQ: XELA ) +23% . YRC Worldwide (NASDAQ: YRCW ) +17% . Zosano Pharma Corporation (NASDAQ: ZSAN ) +16% . BroadVision (NASDAQ: BVSN ) +16% . Ch...

Ovid Therapeutics (NASDAQ: OVID ) prices two separate public offerings of 9M common shares at $2.50/share and 4,000 non-voting Series A Convertible Preferred Stock at $2,500/share (each share of Series A preferred stock is convertible into 1,000 shares of common stock). More news on: Ovi...

Arbutus Biopharma (NASDAQ: ABUS )  -25%  after a decision to  stop development of AB-506. More news on: Arbutus Biopharma Corporation, Ovid Therapeutics Inc., PDS Biotechnology Corporation, Stocks on the move, Read more ...

NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, today announced the pricing of two concurrent but separate underwritten publ...

Ovid Therapeutics (NASDAQ: OVID ) has tumbled 13.1% postmarket after announcing public offerings of common stock and preferred stock. More news on: Ovid Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read more ...

OVID stock is one of the biggest penny stock gainers in the biotech sector this week after Ovid Therapeutics Inc (NASDAQ:OVID) reported preliminary results from a Phase 2 open-label extension study. Positive Momentum Ovid Therapeutics has been one of the more interesting companies in th...